Preclinical Efficacy Failure of Human CNS-Derived Stem Cells for Use in the Pathway Study of Cervical Spinal Cord Injury

• Main Authors: Aileen J. Anderson, Katja M. Piltti, Mitra J. Hooshmand, Rebecca A. Nishi, Brian J. Cummings
• Format: Article
• Language: English
• Published: Elsevier 2017-02-01
• Series: Stem Cell Reports
• Subjects: human neural stem cells (hNSC); spinal cord injury (SCI); cervical; efficacy; good manufacturing practices (GMP); RIGOR; FDA guidelines for cell therapies
• Online Access: http://www.sciencedirect.com/science/article/pii/S2213671116303083

We previously showed the efficacy of multiple research cell lines (RCLs) of human CNS neural stem cells (HuCNS-SCs) in mouse and rat models of thoracic spinal cord injury (SCI), supporting a thoracic SCI clinical trial. Experts recommend in vivo preclinical testing of the intended clinical cell lot/line (CCL) in models with validity for the planned clinical target. We therefore tested the efficacy of two HuCNS-SC lines in cervical SCI: one RCL, and one CCL intended for use in the Pathway Study of cervical SCI in man. We assessed locomotor recovery and sensory function, as well as engraftment, migration, and fate. No evidence of efficacy of the CCL was observed; some data suggested a negative impact of the CCL on outcomes. These data raise questions about the development and validation of potency/comparability assays for clinical testing of cell products, and lack of US Food and Drug Administration requirements for in vivo testing of intended clinical cell lines.